Maravai LifeSciences Holdings Inc
maravai.comWhat Do They Do?
Sells nucleic acid products and enzymes, plus impurity-testing kits and services, to biopharmaceutical companies, research organizations and diagnostics companies.
10-K for FY2025, filed Feb 26, 2026Maravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences…View ↗
complex nucleic acids for therapeutic, vaccine, and diagnostic applications; custom enzymes for research and diagnostic use; and…View ↗
TriLink provides nucleic acid products and related services, including mRNA, oligonucleotides, CleanCap® mRNA capping technology, ModTail™…View ↗
Cygnus provides biologics safety testing products and services, including host cell protein ELISA kits, impurity detection assays, viral…View ↗
We provide products and services that enable the detection of impurities present in bioproduction. Our products are used during development…View ↗
How Do They Make Money?
Both segments mainly sell products, with customers generally paying when goods or services are transferred. Certain custom nucleic acid and antibody-development work is earned over the manufacturing period.
10-K for FY2025, filed Feb 26, 2026Revenue RecognitionView ↗
Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration…View ↗
The Company’s revenue is predominantly recognized at a single point in time, generally upon transferring control to the customer or…View ↗
-
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by reportable segment ↗
$185.7M
-
10-K for FY2025, filed Feb 26, 2026
$185.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
TriLink
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
64% |
TriLink, FY2025
$119.8M Sources
|
Sold outright |
|
Cygnus
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
36% |
Cygnus, FY2025
$66M Sources
|
Sold outright |
Who Are Their Customers?
Biopharmaceutical, diagnostics and life-science customers are served through direct and indirect sales; academic buyers order online, by email or phone, or through partners, while international sales also use distributors.
10-K for FY2025, filed Feb 26, 2026We have relationships with the following categories of customers: developers of therapeutics, cell and gene therapies and vaccines, other…View ↗
We serve customers through direct and indirect sales in each business segment, with a primary focus on our biopharmaceutical and large…View ↗
We address customers outside the United States with a combination of direct sales and distributor partners, supporting customers in…View ↗
Do Revenues Turn Into Profits?
No. It lost $130.8M in FY2025.
10-K for FY2025, filed Feb 26, 2026
−$215.3MView ↗
10-K for FY2025, filed Feb 26, 2026
−$130.8MView ↗
10-K for FY2025, filed Feb 26, 2026
−$70.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$12.4MView ↗
- ▼ −69% (Loss)
- vs −$39.6M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 7, 2026
Open tableView ↗
Shrinking. Revenue fell 77% in 4 years, from $799.2M in FY2021 to $185.7M in FY2025, about 31% a year.
Loading...
